Back to explorer

Bisphosphonate

Zoledronic acid

Zometa · Zol

The tubule-toxic bisphosphonate — ATN driven by dose and infusion speed.

ModerateBisphosphonate · approved 2001
Hypercalcemia of malignancyBone metastasesMyeloma

Signature kidney injury

Acute Tubular Necrosis

Nephrotoxicity is the dose-limiting toxicity but largely avoidable; no precise population rate.

Source: Markowitz et al., Kidney Int 2003

Mechanism of kidney injury

Dose- and infusion-rate-dependent direct proximal tubular toxicity producing acute tubular necrosis.

Clinical presentation

AKI with a rising creatinine, often with partial recovery after withdrawal.

Onset

Acute — days to weeks after infusion(s).

Reversibility

Partially reversible

Anticancer mechanism

Nitrogen-containing bisphosphonate inhibiting osteoclast-mediated bone resorption. Hypercalcemia of malignancy, bone metastases and myeloma.

Management

Hold drug, hydration, supportive care.

Risk factors

  • Rapid infusion
  • High / frequent dosing
  • Pre-existing CKD
  • Volume depletion

Prevention

  • Adequate hydration
  • Slow infusion (≥15 min)
  • Dose-adjust for CrCl
  • Avoid if CrCl < 30–35
Note · The ATN pattern distinguishes it from pamidronate's collapsing FSGS.

Where it strikes

Nephron segments

Proximal Tubule

Bulk reabsorption + drug uptake (OCT2, OATs)

Injury signatures

Acute Tubular Necrosis

Beyond the kidney

Class-level context for the major non-renal toxicities of bisphosphonates.

Musculoskeletal

Myalgia, myositis, rhabdomyolysis, ONJ

  • Osteonecrosis of the jaw, hypocalcemia, acute-phase reaction

Related agents

Other agents sharing the same signature kidney injury.

Cisplatin

Platinol · Platinum agent

Profile

Proximal tubular ATN + magnesium wasting; the archetype.

ATNLYTEPRE
SevereOpen →

Carboplatin

Paraplatin · Platinum agent

Profile

Kidney-sparing; GFR-dosed by the Calvert formula.

ATNLYTE
MildOpen →

Oxaliplatin

Eloxatin · Platinum agent

Profile

Least nephrotoxic platinum; rare immune hemolysis.

ATNTMA
MildOpen →